PIONEER

Prostate cancer diagnosis and treatment enhancement through the power of big data in Europe
PIONEER logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 10
Grant agreement number
777492

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
6 000 000
EFPIA in kind
6 763 500
Total Cost
12 763 500

Summary

Prostate cancer is the second most common cancer in men, and accounts for 9 % of all cancer deaths in men. Currently, it is hard to predict which patients will respond best to different treatments, and which patients can be managed safely without undergoing treatment. The aim of PIONEER is to use big data to address key knowledge gaps related to the screening, diagnosis and treatment of prostate cancer patients. To do this, they will standardise and integrate existing ‘big data’ from sources such as clinical trials and electronic health records into a single, innovative data platform. The project will draw on this database to identify ways to improve prostate cancer outcomes and health system efficiency. The project will apply FAIR (‘findable, accessible, interoperable, and reusable’) principles to the data. Ultimately, the project results should feed back into clinical centres so that patients can benefit from the best possible care.

PIONEER is part of IMI’s Big Data for Better Outcomes (BD4BO) programme.

Participants Show participants on map

EFPIA companies
  • Astellas Pharma Europe BV, Leiden, Netherlands
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Covance Laboratories LTD, Harrogate, United Kingdom
  • Ims Information Solutions Medical Research Limited, London, United Kingdom
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Nv SAS Institute SA, Tervuren, Belgium
  • Orion Oyj, Espoo, Finland
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
  • Association Eisbm, Vourles, France
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • European Alliance For Personalised Medicine Asbl, Brussels, Belgium
  • European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium
  • Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany
  • Goeteborgs Universitet, Gothenburg, Sweden
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • King'S College London, London, United Kingdom
  • Lunds Universitet, Lund, Sweden
  • Stichting Katholieke Universiteit, Nijmegen, Netherlands
  • Tampereen Korkeakoulusaatio Sr, Tampere, Finland
  • Technische Universitaet Dresden, Dresden, Germany
  • The University Court Of The University Of Aberdeen, Aberdeen, United Kingdom
  • Universita Vita-Salute San Raffaele, Milano, Italy
  • Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
  • Weizmann Institute Of Science, Rehovot, Israel
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Ihe, Institutet For Halso- Och Sjukvardsekonomi Aktiebolag, Lund, Sweden
  • International Consortium For Healthoutcomes Measurement LTD, London, United Kingdom
  • Pinsent Masons Llp, London, United Kingdom
  • Stichting European Urological Foundation, Arnhem, Netherlands
  • The Ecancer Global Foundation, Bristol, United Kingdom
  • The Hyve BV, Utrecht, Netherlands
  • Ttopstart BV, Bilthoven, Netherlands
Patient organisations
  • European Cancer Patient Coalition, Brussels, Belgium

CONTACT

Project coordinator
James N'DOW
STICHTING EUROPEAN UROLOGICAL FOUNDATION
j.ndow[at]abdn.ac.uk
Project leader
Alex ASIIMWE
BAYER
alex.asiimwe[at]bayer.com